SEC Comment Letter for Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260) (FBIO) — May 22, 2020

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)
Date: May 22, 2020 · CIK: 0001429260 · Accession: 0000000000-20-004603

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-238327

Date

May 22, 2020

Author

Lindsay A. Rosenwald, M.D.

Form

UPLOAD

Company

Fortress Biotech, Inc. (FBIO, FBIOP) (CIK 0001429260)

Letter

United States securities and exchange commission logo May 22, 2020 Lindsay A. Rosenwald, M.D. Executive Chairman, Chief Executive Officer and President Fortress Biotech, Inc. 2 Gansevoort Street, 9th Floor New York, New York 10014 Re:Fortress Biotech, Inc. Registration Statement on Form S-3 Filed May 18, 2020 File No. 333-238327 Dear Dr. Rosenwald: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark McElreath, Esq.

Show Raw Text

United States securities and exchange commission logo
May 22, 2020
Lindsay A. Rosenwald, M.D.
Executive Chairman, Chief Executive Officer and President
Fortress Biotech, Inc.
2 Gansevoort Street, 9th Floor
New York, New York 10014
Re:Fortress Biotech, Inc.
Registration Statement on Form S-3
Filed May 18, 2020
File No. 333-238327
Dear Dr. Rosenwald:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Mark McElreath, Esq.

SecProbe.io